Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. - Wikidata - wikimedia - TriplyDB

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

http://www.wikidata.org/entity/Q34394358

about

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results.Towards improved cancer diagnosis and prognosis using analysis of gene expression data and computer aided imaging.Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation Trastuzumab emtansine: mechanisms of action and drug resistance Geldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat-shock protein 90 kDa after exposure to ionizing radiation Validation of an algorithm for the nonrigid registration of longitudinal breast MR images using realistic phantoms.Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy.Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast The human cancer genome project--one more misstep in the war on cancer.BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts Targeting the function of the HER2 oncogene in human cancer therapeutics.Effects of hormone deprivation and 2-methoxyestradiol combination therapy on hormone-dependent prostate cancer in vivo.Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.Postoperative endocrine therapy for invasive breast cancer.Prospective evaluation of the feasibility of sentinel lymph node biopsy in breast cancer patients with negative axillary conversion after neoadjuvant chemotherapy.The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer.Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.Clinical development of phosphatidylinositol-3 kinase pathway inhibitors Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.Early prediction of the response of breast tumors to neoadjuvant chemotherapy using quantitative MRI and machine learning Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.Cell death signaling and anticancer therapy Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro.Targeting HER2 Positive Breast Cancer with Chemopreventive Agents.Cancer immunotherapy: Progress and challenges in the clinical setting.

P2860

Q27851705-8153D04A-D2D8-4D6D-BAB9-027B185A9416 Q28729012-2F292132-33D9-43A8-856B-73DBEE5C5E1C Q29617584-941750F4-3DEA-4DA4-9786-6B1038FB2BE9 Q31092479-F166703F-322B-4826-B45E-BD6A715ABEEB Q33459037-1811DA3B-37FF-4A06-8ADE-B8A48E4F44E8 Q33508763-9AFF0FA4-0140-4789-B973-F80A2121B098 Q33641143-4D7DE18A-AC61-41F9-90A6-CB62DB3D2339 Q33644305-F5F96263-BD86-48C2-9EAB-ACAF8C7DD315 Q33739796-6523FBF8-9D4E-4938-BD80-39B7ADDD3680 Q33759627-C1055012-6F6D-4E88-846B-5739265E2AEB Q33825349-DF8E1DD4-0BE5-4867-A8B3-2CE009165354 Q33898515-8B37E30B-C3FC-4560-947B-5D42D07FDCD8 Q34189855-27F71924-ADF8-46A9-85D2-1489F6E12B23 Q34205196-BE549353-41AE-46EF-A120-8ECE43F12453 Q34380366-490463E9-1B5F-4087-8732-11E987B4B463 Q34416425-78978C68-DA8B-49E2-ABD6-5959B8D4F151 Q34632169-3F33BF22-E6B5-4FCC-84D0-3747577BD27A Q34679149-99E0862A-F221-4D1B-A9C2-ADEB162AC2C7 Q34694605-6ABC45FF-BCE4-4783-AEEE-12C96DED265D Q34766486-C79E7960-25B1-4488-928C-AE328F93084A Q34769708-152F8BB5-C380-4887-B73D-A8FCB31EFA91 Q34781067-B9B8048D-39AF-429B-A64A-D6D927FD2A78 Q34910095-1226FCD5-3B9C-479A-BFC6-646FCDCBEFAA Q34977181-AA4DEEFA-A6F0-4C3B-87FF-F1D9B7208D0A Q35555254-8A3429B3-C28B-4914-8CD7-43499E7A65C5 Q35566231-D2030077-4813-4299-8803-33DB40C6B071 Q35566234-F02FA6F1-C2A4-4B92-879D-C27B807874EF Q35624814-D58D0C66-F422-4887-9F97-457CF4E76E91 Q35625048-F84502D7-8CFB-4B95-8F94-92FD7EFB60E4 Q35663802-8C79448E-2832-446D-89D3-DDCA3716CCB6 Q35779022-CCED9BE9-6E15-415E-92EA-3482FBBD6C5E Q35780315-A04D62B3-15FE-4180-9944-3795E378DF5A Q35889621-C2A92956-EDE9-44FF-A5C5-0F2D67F2A69B Q35972102-BB8E9658-A8F9-416C-A678-C73B700CF262 Q35999582-B302089A-E938-42CD-B08B-E0A67582586F Q36021424-07073796-E698-4DAF-8D9E-A515356E462A Q36088788-6C410BB2-3E7E-4F6F-A309-8B51E8D76DE3 Q36095351-569DAD32-B1DA-4EA4-857D-46F43C35222C Q36114852-A88E18AE-8BA3-431C-BABD-AFBC85523171 Q36184314-3771193D-9767-483E-843A-D75A95237554

P2860

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

http://www.wikidata.org/entity/Q34394358

description

2005 nî lūn-bûn

@nan

2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

@ast

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

@en

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

@nl

type

label

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

@ast

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

@en

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

@nl

prefLabel

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

@ast

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

@en

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

@nl

P1433

Q34394358-A91E4F22-FE60-4166-9C84-AB24A93E1B2B

P1476

Q34394358-168AEBAB-24FB-4CA5-8E10-DF7CF53E3434

P2093

Q34394358-1CADC3DE-07EE-41BE-96DF-5C5A74034B64

Q34394358-2B0812E1-E321-4D94-A507-2D6B154306FF

Q34394358-3BCB19C6-B815-4F9F-A980-E02E574547DC

Q34394358-556816CC-67D8-474A-99EB-A18B5CC5253A

Q34394358-63E99D92-A983-4201-AD0F-A6C9DCED22C6

Q34394358-6D195EF8-ECE1-43AD-998F-B5549F304543

Q34394358-70D8D545-CF23-47B4-8150-C24066D24DFA

Q34394358-AFA56962-DCFE-48C9-B102-A9CB8AA020A2

Q34394358-C20E2C3E-BCE7-45B2-83FA-46ED0F0A87EE

Q34394358-C3C7190C-A46D-4CBE-A2CA-BEA077601BBC

P304

Q34394358-D97C9B32-5529-47D8-A8E8-06A94C85B6A3

P31

Q34394358-B6FDCD2B-00B8-4564-AE16-91F4935E4BD1

P356

Q34394358-B261207C-951D-468B-A6CD-5439764A2249

P407

Q34394358-221C5CEF-E805-46E9-B3E4-685B2DBBB758

P433

Q34394358-224AA0E9-DC6B-420D-BD1B-1D8B137C7428

P478

Q34394358-6DC31543-A600-47E1-AEC8-A1D42090A0D9

P577

Q34394358-BA0A6655-3D45-45A6-BF83-4AE4BB584184

P698

Q34394358-5116E705-1962-4F5E-B089-37044C273842

P356

JCO.2005.00.661

P1433

Journal of Clinical Oncology

P1476

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

@en

P2093

C Kent Osborne

http://www.w3.org/2001/XMLSchema#string

Chun-Xia Wang

http://www.w3.org/2001/XMLSchema#string

D Craig Allred

http://www.w3.org/2001/XMLSchema#string

Gary C Chamness

http://www.w3.org/2001/XMLSchema#string

Heidi L Weiss

http://www.w3.org/2001/XMLSchema#string

Jenny C Chang

http://www.w3.org/2001/XMLSchema#string

M Carolina Gutierrez

http://www.w3.org/2001/XMLSchema#string

Michael P Digiovanna

http://www.w3.org/2001/XMLSchema#string

Rachel Schiff

http://www.w3.org/2001/XMLSchema#string

Richard Elledge

http://www.w3.org/2001/XMLSchema#string

P304

2460-2468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.00.661

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15710948

http://www.w3.org/2001/XMLSchema#string